Company intelligence / Profile preview

Empyrean International

New York, NY, United Stateseisdhaka.com ↗

Ownership: Private
Development stage: Other

Overview

Empyrean Neuroscience has developed a proprietary genetic engineering platform to modify fungal and plant genomes, enabling production of optimized neuroactive small molecules. Their lead programs are in preclinical development targeting CNS disorders such as depression, PTSD, substance use disorders, chronic pain, panic disorder, OCD, psychotic disorders. IND-enabling studies are underway with plans to enter clinical trials for MDD.

Therapeutic areas: PsychiatryNeurology
Modalities: Small moleculeChemical drugsFungal alkaloidsCannabinoids
Industry: Biotech

Partnerships

None publicly disclosed as of latest available information.

Beyond the preview

Go deeper on Empyrean International.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Empyrean International.

Explore the full profile